Preliminary Final Report
Preliminary Final Report: Download here.
ASX Announcements
Appendix 3B – New Issue Announcement
Appendix 3B – New issue announcement, application for quotation of additional securities and agreement: Download here.
InvitroCue Signs Strategic Partnership Agreement With QIAGEN Suzhou
August 22, 2016 – InvitroCue Limited (ASX:IVQ) has announced that its wholly owned subsidiary InvitroCue Biomedical Service Suzhou (“InvitroCue Suzhou”) has signed a Strategic Partnership Agreement with QIAGEN Suzhou Translational Medicine Co. Limited (“QIAGEN Suzhou”). Pursuant to the agreement, InvitroCue Suzhou and QIAGEN Suzhou will jointly accelerate the discovery of biomarkers and translational medicine …
Escrow Release
Escrow Release Click here to download.
InvitroCue Announces New Program Focused on Hepatitis B Virus
July 28, 2016 – InvitroCue (ASX:IVQ), has signed a research collaboration program with Yong Loo Lin School of Medicine, National University of Singapore. The program will focus on InvitroCue’s “3D human liver” to model an in vitro system for the study of chronic Hepatitis B infection. If the program delivers promising data and results by …
Appendix 4C – Quarterly Report
Quarterly Report : Appendix 4C
Investment Fact Sheet July 2016
Download the Investment Fact Sheet here.
InvitroCue Commences Pancreatic Toxicity Assay Development
11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. …
Notification of Change of Auditor
Notification of Change of Auditor Click here to download
Investor Presentation (Mandarin)
Download the Investor Presentation translated in Simplified Mandarin. Refer to the announced English version herein.